NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$10.12
-0.12 (-1.17 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.00
$10.28
50-Day Range
$9.00
$10.39
52-Week Range
$4.98
$13.20
Volume1,505 shs
Average Volume24,782 shs
Market Capitalization$78.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
30 days | 90 days | 365 days | Advanced Chart
Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.


About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.58 out of 5 stars

Medical Sector

1493rd out of 2,218 stocks

Diagnostic Substances Industry

28th out of 38 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

Is ImmuCell a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmuCell stock.
View analyst ratings for ImmuCell
or view top-rated stocks.

What stocks does MarketBeat like better than ImmuCell?

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmuCell?

ImmuCell saw a decrease in short interest in July. As of July 15th, there was short interest totaling 7,800 shares, a decrease of 25.7% from the June 30th total of 10,500 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company's shares are short sold.
View ImmuCell's Short Interest
.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) posted its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks' consensus estimate of $0.05 by $0.11. The biotechnology company earned $4.11 million during the quarter. ImmuCell had a negative net margin of 9.22% and a negative trailing twelve-month return on equity of 4.77%.
View ImmuCell's earnings history
.

How has ImmuCell's stock been impacted by Coronavirus?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICCC stock has increased by 135.3% and is now trading at $10.12.
View which stocks have been most impacted by COVID-19
.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell updated its second quarter 2021 earnings guidance on Wednesday, July, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.50 million-$4.50 million, compared to the consensus revenue estimate of $3.26 million.

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 60, Pay $354.27k)
  • Dr. Joseph H. Crabb Ph.D., VP & Chief Scientific Officer (Age 66, Pay $54.98k)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 44, Pay $314.8k)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 65, Pay $255.65k)
  • Elizabeth S. Toothaker, Director of Fin. & Admin.
  • Mr. A. Gustavo Scaffa, Sr. Director of Quality
  • John W. Zinckgraf, Director of Product Devel.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $10.12.

How much money does ImmuCell make?

ImmuCell has a market capitalization of $78.33 million and generates $15.34 million in revenue each year. The biotechnology company earns $-1,020,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does ImmuCell have?

ImmuCell employs 52 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

Where are ImmuCell's headquarters?

ImmuCell is headquartered at 56 EVERGREEN DR, PORTLAND ME, 04103.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.